Exyte has completed the integration of Pharmaplan into its biopharma and life sciences division, creating a unified engineering platform for the design and delivery of GMP facilities across Europe.
The merger brings Pharmaplan’s specialist teams and locations under the Exyte banner, combining decades of life-sciences expertise with global engineering and construction capacity.
“Bringing Pharmaplan fully into Exyte combines global delivery scale with five decades of life‑sciences process and GMP expertise,” said Dr Wolfgang Büchele, CEO of Exyte.
Exyte first announced the acquisition in September 2024 as part of a strategy to deepen engagement with rapidly growing biotech and pharmaceutical markets across Europe.
The integration strengthens Exyte’s ability to respond to rising demand for rapid-to-market, compliant facilities, including advanced therapies and cell and gene therapy production spaces.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.
Subscribe now Already a subscriber? Sign in here.